



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,354	06/21/2006	Jorn Bullerdiek	14677-007US	1121
61263	7590	07/16/2009	EXAMINER	
PROSKAUER ROSE LLP			SHEN, WU CHENG WINSTON	
1001 PENNSYLVANIA AVE, N.W.,				
SUITE 400 SOUTH			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20004			1632	
			MAIL DATE	DELIVERY MODE
			07/16/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/541,354	BULLERDIEK, JORN	
	Examiner	Art Unit	
	WU-CHENG Winston SHEN	1632	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 22 June 2009.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 92-101 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 92-101 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

- Certified copies of the priority documents have been received.
- Certified copies of the priority documents have been received in Application No. _____.
- Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____ .	6) <input type="checkbox"/> Other: _____ .

DETAILED ACTION

Claim amendments filed on 06/22/2009 have been received and entered. Claims 1-91 are cancelled. Claims 92-101 are newly added.

The Election/Restrictions documented in this office action is necessitated by claim amendments filed on 06/22/2009, which is part of Applicant's response to the Non-Final office action mailed on 12/22/2009.

Election/Restrictions

It is noted that Applicant's election of Group II, claims 1 and 3, drawn to "use claim" that was interpreted as a method of using the *translation product(s)* thereof one or several nucleic acid(s) in a process, whereby the process is selected from the group comprising angiogenesis, neovascularization, transmyocardial revascularization, wound healing, angiogenesis following wounding, epithelialization and healing of tooth and bone implants, whereby the nucleic acid(s) is/are one(s) that code(s) for high mobility group (HMG) proteins, including HMGB 1 or a part thereof, in the reply filed on 09/18/2008 has been acknowledged previously. In response to further restriction documented on page 12 of the Elections/Restriction mailed on 06/18/2008, Applicant elected the process of angiogenesis. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

In response to non-Final office action mailed on 12/22/2008, Applicant cancels all previously pending claims 1-91, and new claims 92-101 are added in the reply filed on 06/22/2009.

Newly added independent claim 92 reads as follows: A method of promoting angiogenesis in a tissue or part thereof, comprising incubating a tissue or part therefore with a translation product of a high mobility growth protein gene, or a fragment thereof and, optionally, obtaining or recovering the tissue or an intermediate thereof. Claims 93-101 depend from claim 92. The Examiner acknowledges that newly added claim 92 is encompassed by the elected Group II invention, and claims 92 and its dependent claims 93-98, 100, and 101, can be examined as continuous prosecution of elected Group II invention. However, claim 99 is directed to the method according to claim 92, further comprising incubating said tissue or fragment thereof with a translation product derived from the VEGF gene or a fragment thereof. The translation product derived from the VEGF gene or a fragment thereof recited in claim 99 is not encompassed by elected Group II invention. Therefore, claim 99 is assigned to a new group, Group XXVII (the Restriction requirement mailed on 06/18/2008 listed Group I-XXVI). Moreover, the following requirement for election of species pertaining to claims 92-98, 100, and 101 is necessitated by claim amendments filed on 06/22/2009

1. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

(i) Claim 93: translation product HMGB1, translation product HMGB2, and translation product HMGB3. These are different HMGB proteins belonging to HMGB family with distinct amino acid sequences, and different in structures and functions.

(ii) Claim 95: translation product HMGA1a, translation product HMGA1b, translation product HMGA1c, and translation product HMGA2. These are different HMGA proteins belonging to HMGA family with distinct amino acid sequences, and different in structures and functions.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

2. Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction were not required because the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103 (a) of the other invention.

3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication from the examiner should be directed to Wu-Cheng Winston Shen whose telephone number is (571) 272-3157 and Fax number is 571-273-3157. The examiner can normally be reached on Monday through Friday from 8:00 AM to 4:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the supervisory patent examiner, Peter Paras, Jr. can be reached on (571) 272-4517. The fax number for TC 1600 is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Wu-Cheng Winston Shen/
Patent Examiner
Art Unit 1632